TRIV-920 is a first-in-class monoclonal antibody in preclinical development for the treatment of pancreatitis.
TRIV-920 is a first-in-class monoclonal antibody engineered to potently inhibit active trypsin 1 and 2. It is currently in preclinical development for the treatment of pancreatitis, a condition with high unmet medical need and no approved targeted therapies.
In preclinical models of hereditary pancreatitis (hPRSS1R122H), TRIV-920 has demonstrated significant reduction in key markers of both acute and chronic pancreatic damage, highlighting its potential as a first-in-class treatment option for patients with pancreatitis.
Cibus Therapeutics
CBT-101
cibustherapeutics.com
GondolaBio
Hereditary Pancreatitis Program
gondolabio.com
CCKr Therapeutics
Proglumide
cckrtherapeutics.com
| Attribute | Triv-920 | CBT-101 | Hereditary Pancreatitis Program | Proglumide | |
|---|---|---|---|---|---|
| Provider | | | | CCKr Therapeuticscckrtherapeutics.com | |
| Founded | 2023 | 2025 | 2024 | — | |
| Sells To | B2B, Enterprise | Patients | — | Patients | |
| Pricing Model | Licensing, Pre-Revenue | Pre-Revenue | — | — | |
| Ownership | Private, Venture-backed | Private | Venture-backed | — |
Provider
Founded 2023
Sells To B2B, Enterprise
Pricing Model Licensing, Pre-Revenue
Ownership Private, Venture-backed
Provider
Founded 2025
Sells To Patients
Pricing Model Pre-Revenue
Ownership Private
Provider
Founded 2024
Sells To —
Pricing Model —
Ownership Venture-backed
Provider CCKr Therapeuticscckrtherapeutics.com
Founded —
Sells To Patients
Pricing Model —
Ownership —
Arwin HealthFc-SPINK1 is a first-in-class Fc-fusion biologic in preclinical development for hereditary and genetic forms of pancreatitis.
CBT-248 is an oral small-molecule anti-inflammatory in preclinical development for hereditary pancreatitis and chronic pancreatitis.
Fc-SPINK1 is a first-in-class Fc-fusion biologic in preclinical development for hereditary and genetic forms of pancreatitis.
Arwin HealthCBT-248 is an oral small-molecule anti-inflammatory in preclinical development for hereditary pancreatitis and chronic pancreatitis.
